JMP Securities Initiates Coverage On Structure Therapeutics with Market Outperform Rating, Announces Price Target of $90
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jonathan Wolleben has initiated coverage on Structure Therapeutics (NASDAQ:GPCR) with a Market Outperform rating and a price target of $90.
October 19, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Structure Therapeutics has been given a Market Outperform rating by JMP Securities with a price target of $90.
The initiation of coverage by JMP Securities with a Market Outperform rating and a price target of $90 indicates a positive outlook for Structure Therapeutics. This could potentially attract more investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100